Clinical trials: Squamous Cell Carcinoma of Cervix
Stage IB2 Cervical Cancer, Stage II Cervical Cancer
Evaluation of Hysterectomy After Chemoradiation Therapy for Stage IB2/II Cervical Cancer
GYNECO 02 hypothesis is that hysterectomy reduces the possibility of local or loco-regional relapse, especially in patient with a reduced metastatic risk and who received a local chemoradiation therapy with an increase of…
- Conditions
- Stage IB2 Cervical Cancer, Stage II Cervical Cancer, Adenocarcinoma, Squamous Cell Carcinoma
- Trial name
- NCT01363466
- Testing
- hysterectomy
- Where
- 35 sites in France
- Volunteers
- 61 people
- Sponsor
- UNICANCER
Cervical Cancer
Arsenic Trioxide in Treating Patients With Stage IVB or Recurrent Cervical Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have stage…
- Trial name
- NCT00005999
- Testing
- arsenic trioxide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cervical Cancer
Phase II Study of Pazopanib and Topotecan in Cervical Cancer
The goal of this clinical research study is to learn if the combination of topotecan and pazopanib can help to control recurrent cervical cancer. The safety of the study drug combination will also be studied.
- Trial name
- NCT02348398
- Testing
- Pazopanib, Topotecan, Phone Call
- Sponsor
- M.D. Anderson Cancer Center
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer
This phase I trial is studying the side effects and best dose of cetuximab when given together with cisplatin and radiation therapy in treating patients with stage IB, stage II, stage III, or stage IVA cervical cancer.
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma
- Trial name
- NCT00104910
- Testing
- Internal Radiation Therapy, 3-Dimensional Conformal Radiation Therapy, Cetuximab
- Where
- 15 sites in United States
- Volunteers
- 64 people
- Sponsor
- Gynecologic Oncology Group
Vulvar Cancer, Cervical Cancer
Screening for Anal Cancer in Women With High-grade Vulvar Dysplasia or Vulvar Cancer.
Almost half of all women will develop an HPV infection in their lifetime. While most infections are naturally asymptomatic or cleared by the immune system, some persist and can lead to the development of cervical, vulvar, or anal…
- Conditions
- Vulvar Cancer, Cervical Cancer, Vulvar Dysplasia, Cervical Dysplasia
- Trial name
- Vulvar-AIN (NCT03061435)
- Testing
- Screening anal Pap smear - No high-resolution anoscopy, Screening anal Pap smear - High-resolution anoscopy
- Where
- Canada
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Dr. Danielle Vicus
Melanoma, Non Small Cell Lung Cancer
Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors
AI-061 is a co-formulation drug product (DP) consisting of 1:1 ratio mix of AI-025, an anti-PD-1 antibody, and ONC-392, an anti-CTLA-4 antibody.
- Conditions
- Melanoma, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, High Grade Serous Adenocarcinoma of Ovary
- Trial name
- PRESERVE-009 (NCT05858736)
- Testing
- AI-061
- Where
- 5 sites in Australia
- Volunteers
- 18 people
- Sponsor
- OncoC4, Inc.
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
Pelvic Exenteration in Treating Patients With Recurrent Cervical Cancer
This phase II trial is studying how well pelvic exenteration works in treating patients with recurrent cervical cancer. Pelvic exenteration may be effective in treating recurrent cervical cancer.
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma
- Trial name
- NCT00217633
- Testing
- Conventional Surgery
- Where
- 39 sites in United States, Spain
- Volunteers
- 38 people
- Sponsor
- Gynecologic Oncology Group
Cervical Cancer, Head and Neck Squamous Cell Carcinoma
HRYZ-T101 Injection for HPV18 Positive Solid Tumor
A multicenter, open label, single arm dose escalation phase I study to evaluate the safety, tolerability, and efficacy of HRYZ-T101 injection for HPV18 positive solid tumor.
- Conditions
- Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Carcinoma of Vagina, Carcinoma of Penis
- Trial name
- NCT05952947
- Testing
- HRYZ-T101 Injection, Fludarabine + Cyclophosphamide
- Where
- China
- Volunteers
- 32 people
- Sponsor
- HRYZ Biotech Co.
Cervical Adenocarcinoma, Cervical Adenocarcinoma In Situ
Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer in Patients With Cervical, Vaginal and Vulvar Dysplasia and Cancer
This trial studies the prevalence of anal dysplasia and anal cancer in patients with cervical, vaginal, and vulvar dysplasia and cancer.
- Conditions
- Cervical Adenocarcinoma, Cervical Adenocarcinoma In Situ, Cervical Intraepithelial Neoplasia, Cervical Squamous Cell Carcinoma, Not Otherwise Specified
- Trial name
- NCT02140021
- Testing
- Biospecimen Collection, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 409 people
- Sponsor
- M.D. Anderson Cancer Center
Cervical Cancer
Surgery and Vaccine Therapy in Treating Patients With Early Cervical Cancer
RATIONALE: Vaccines made from human papillomavirus may make the body build an immune response to and kill cervical cancer cells. Combining vaccine therapy with surgery may be a more effective treatment for cervical cancer.
- Trial name
- NCT00002916
- Testing
- human papillomavirus 16 E7 peptide, synthetic human papillomavirus 16 E6 peptide, adjuvant therapy
- Where
- 10 sites in Austria, France and 5 more
- Volunteers
- 44 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Cervical Abnormalities, Cervical Intraepithelial Neoplasia Grade 2/3
Optimal Strategy for the Management of ASCUS Cytology in Health Care Services of Medellin, Colombia
Cervical cancer as well cervical preneoplastic abnormalities (CIN2+) are cause by human papillomavirus (HPV) infection. These abnormalities have been historically detected by cervical cytology, but recent evidence shows that HPV…
- Conditions
- Cervical Abnormalities, Cervical Intraepithelial Neoplasia Grade 2/3, Cervical Cancer
- Trial name
- ASCUS-COL (NCT02067468)
- Testing
- HPV test, COLPOSCOPY, cytology
- Where
- Colombia
- Volunteers
- 2,661 people
- Sponsor
- Universidad de Antioquia
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
Phase I trial to study the effectiveness of erlotinib in treating patients who have metastatic or unresectable solid tumors and liver or kidney dysfunction.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma
- Trial name
- NCT00030498
- Testing
- erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer Metastatic, Renal Cell Carcinoma
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
Immunotherapy (IO), such as treatment with anti-PD-1, PD-L1, or CTLA-4 inhibitors, is a rapidly expanding treatment for multiple metastatic cancers with improved survival for certain cancers.
- Conditions
- Lung Cancer Metastatic, Renal Cell Carcinoma, Head and Neck Cancer, Triple Negative Breast Cancer
- Trial name
- MOIO (NCT05078047)
- Testing
- Reduced dose intensity of IO
- Where
- 33 sites in France
- Volunteers
- 646 people
- Sponsor
- UNICANCER
Metastatic Cancer, Solid Tumor
Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies
The primary purpose of this study is to see if Sym024 is safe and tolerable as monotherapy and in combination with Sym021 in patients with solid tumor malignancies.
- Trial name
- NCT04672434
- Testing
- Sym021, Sym024
- Where
- 4 sites in United States, Canada
- Volunteers
- 48 people
- Sponsor
- Symphogen A/S
Human Papillomavirus Infection, Cervical Cancer
Clinical Evaluation of Detection of High Risk HPV in Urine
Cervical cancer is one of the most common tumors in women, which seriously threatens women's life quality and safety. Human papilloma virus (HPV) infection is the most common cause of cervical cancer.
- Conditions
- Human Papillomavirus Infection, Cervical Cancer, Human Papilloma Virus, Negative for Intraepithelial Lesion or Malignancy
- Trial name
- Urine-hrHPV (NCT05210348)
- Where
- 3 sites in China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Peking University People's Hospital
Ovary Cancer, Cervix Cancer
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
The purpose of the trial is to establish the tolerability of HuMax-TF-ADC in a mixed population of patients with specified solid tumors.
- Conditions
- Ovary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer
- Trial name
- NCT02001623
- Testing
- Tisotumab Vedotin (HuMax-TF-ADC)
- Where
- 29 sites in United States, Belgium and 3 more
- Volunteers
- 195 people
- Sponsor
- Seagen Inc.
Papillomavirus Infections, Cervical Intraepithelial Neoplasia
E7 TCR T Cells for Human Papillomavirus-Associated Cancers
Background: Human papillomavirus (HPV) can cause cervical, throat, anal, and genital cancers. Cancers caused by HPV have an HPV protein called E7 inside of their cells.
- Conditions
- Papillomavirus Infections, Cervical Intraepithelial Neoplasia, Carcinoma In Situ, Vulvar Neoplasms
- Trial name
- NCT02858310
- Testing
- E7 TCR cells, Aldesleukin, Fludarabine
- Where
- 2 sites in United States
- Volunteers
- 224 people
- Sponsor
- National Cancer Institute (NCI)
Cervical Cancer, Cervical Cancer Metastatic
QL1706 in Patients With Recurrent and Metastatic Cervical Cancer Resistant to Prior PD-1/PD-L1 Antibody Therapy
To explore the efficacy and safety of administrating QL1706 in patients with recurrent and/or metastatic cervical cancer who had developed resistance to prior PD-1/PD-L1 antibody therapies.
- Conditions
- Cervical Cancer, Cervical Cancer Metastatic, Cervical Cancer Recurrent, Cervical Adenocarcinoma
- Trial name
- NCT07141186
- Testing
- QL1706 (bispecific antibody targeting PD-1 and CLTA-4)
- Volunteers
- 50 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Cervical Cancer, Chemoradiotherapy
Toripalimab Combined With Definitive CCRT for LACC Patients
Cervical cancer constitutes a significant health burden for women globally. While most patients with early-stage disease can be cured with radical surgery or chemoradiotherapy, patients with high-risk locally advanced disease or…
- Conditions
- Cervical Cancer, Chemoradiotherapy, Immunotherapy
- Trial name
- NCT06256224
- Testing
- Toripalimab, CCRT
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Ruijin Hospital
Metastatic Solid Tumor, Recurrent Solid Tumor
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer.
- Conditions
- Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
- Trial name
- NEXUS-01 (NCT06465069)
- Testing
- LY4052031, Pembrolizumab
- Where
- 39 sites in United States, Australia and 6 more
- Volunteers
- 460 people
- Sponsor
- Eli Lilly and Company